Teva Baltics, part of Teva Pharmaceutical Industries, one of the world’s largest generic drug manufacturers, is set to expand its pharmaceutical plant in Vilnius with the addition of two new floors and nearly 30 new employees, the Verslo Zinios online business site reported on Thursday
The expansion is aimed at increasing the production of medicines for infectious diseases.
According to the website, the expansion of research and development capacities will increase the annual production capacity from 5,300 to 5,550 liters. The new premises are expected to become operational in the second quarter of 2026.
Teva Baltics posted over 150 million euros in revenue last year, a 38 percent increase from 2022. Earnings before interest and other similar income and expenses and before tax almost trebled to 53.9 million euros.
The company is 100 percent owned by Rakepoll Holding, a Dutch subsidiary of Teva Pharmaceutical Industries.
Source: BNS
(Reproduction of BNS information in mass media and other websites without written consent of BNS is prohibited.)